Core Viewpoint - Rallybio Corporation (RLYB) shares dropped 41.2% after the company halted the development of RLYB212 due to insufficient pharmacokinetic data from a phase II study [1][2] Group 1: Company Developments - RLYB212 was intended to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT) in pregnant women at risk but failed to meet target concentrations necessary for efficacy [1][2] - Following the setback with RLYB212, the company is now focusing on its lead candidate, RLYB116, which is a differentiated C5 inhibitor aimed at treating complement-driven diseases [4] - Rallybio plans to initiate dosing in a confirmatory pharmacokinetic/pharmacodynamic study for RLYB116 in the second quarter of 2025, targeting diseases such as paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and antiphospholipid syndrome (APS) [5] Group 2: Market Performance - Year to date, Rallybio shares have declined 74%, significantly underperforming the industry, which has seen an 8.9% decline [3] - The management estimates that the market opportunity for complement-mediated diseases like PNH, APS, and gMG exceeds $6 billion [8]